Given the controversy surrounding the management of early-stage
ovarian cancer, we performed a population-based analysis to examine
the quality of care and outcomes for women with early-stage ovarian
cancer. Specifically, we explored the adherence to guideline-based recommendations
for the administration of adjuvant chemotherapy and
analyzed the influence of the duration of chemotherapy on survival
for early-stage, high-risk patients